 Viral Load
"Viral Load" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
| Descriptor ID |
D019562
|
| MeSH Number(s) |
E01.370.225.875.950 E05.200.875.950 G06.920.850
|
| Concept/Terms |
Viral Load- Viral Load
- Load, Viral
- Viral Burden
- Burden, Viral
|
Below are MeSH descriptors whose meaning is more general than "Viral Load".
Below are MeSH descriptors whose meaning is more specific than "Viral Load".
This graph shows the total number of publications written about "Viral Load" by people in this website by year, and whether "Viral Load" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 1 | 3 | 4 | | 2000 | 2 | 2 | 4 | | 2001 | 0 | 3 | 3 | | 2002 | 1 | 4 | 5 | | 2003 | 1 | 5 | 6 | | 2004 | 0 | 10 | 10 | | 2005 | 1 | 6 | 7 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 6 | 6 | | 2008 | 2 | 10 | 12 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 12 | 12 | | 2011 | 5 | 16 | 21 | | 2012 | 4 | 13 | 17 | | 2013 | 3 | 15 | 18 | | 2014 | 1 | 18 | 19 | | 2015 | 5 | 14 | 19 | | 2016 | 8 | 17 | 25 | | 2017 | 0 | 21 | 21 | | 2018 | 6 | 20 | 26 | | 2019 | 4 | 18 | 22 | | 2020 | 2 | 11 | 13 | | 2021 | 4 | 15 | 19 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 11 | 11 | | 2024 | 5 | 7 | 12 | | 2025 | 1 | 13 | 14 | | 2026 | 1 | 6 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Viral Load" by people in Profiles.
-
Oyaro P, Basha GW, Thomas KK, Brown E, Hassan SA, Imran R, Karauki E, Yongo N, Maheria P, Patel RC, Abuogi LL. Predictors of Sustained Viral Suppression among Children Living with HIV in Kenya: Secondary Analysis of Data from a Randomized Control Study. J Pediatric Infect Dis Soc. 2026 Jun 12; 15(6).
-
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.
-
Mann SC, Lykins D, Coyle RP, Witt MD, Kim EY, Macatangay B, Brown TT, Dionne JA, Alcaide M, Lahiri CD, Ramirez C, Dumond JB, D'Souza G, Cohen MH, Wilson TE, Kassaye S, Tien PC, Adedimeji AA, Ellison L, Brooks KM, Bushman LR, Anderson PL, MaWhinney S. In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort. Clin Infect Dis. 2026 Apr 30; 82(4):575-582.
-
Ombajo LA, Nkuranga J, Penner J, Kamau EW, Ismael N, Munseri P, Ayakaka I, Labhardt N, Wamalwa D, Ramgi P, Chissumba RM, Wagude J, Bakari M, Omodi V, Otieno E, Abuogi L, Patel R, Opondo C, Grint D, King'wara L, Macharia A, Mulwa A, Amoth P. The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol. PLoS One. 2026; 21(3):e0330792.
-
Wamakima B, Diouf K, Modest A, Macharia A, Boikanyo K, Hanson SJ, Diseko M, Mabuta J, Rubgega F, Morroni C, Caniglia E, Jackson-Gibson M, Makhema J, Hofmeyr J, Zash R, Shapiro R, Luckett R. Pre-Eclampsia Rates in Women With and Without HIV in Modern ART Era in Botswana. J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):241-248.
-
Serghides L, Lee J, Jacobson DL, Geffner ME, DiMeglio LA, McFarland EJ, Powis KM, Williams PL, Jao J. Brief Report: Is Gestational Exposure to HIV and Protease Inhibitors Associated With Timing of Pubertal Onset? J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):302-307.
-
Hossen F, Kouwaki T, Fujiwara Y, Tsutsuki H, Zhang T, Guo C, Rahman A, Komohara Y, Oshiumi H, Sawa T. Therapeutic Efficacy of the Supersulfide Donor NAC-S2 in Influenza Virus Pneumonia via Suppression of Excessive Inflammatory Responses. Microbiol Immunol. 2026 Mar; 70(3):148-159.
-
Moore CM, Secor EA, Everman JL, Fairbanks-Mahnke A, Jackson N, Pruesse E, Diener K, Morin A, Arbes SJ, Bacharier LB, Bendixsen CG, Calatroni A, Dupont WD, Furuta GT, Gebretsadik T, Gruchalla RS, Gupta RS, Khurana Hershey GK, Kattan M, Liu AH, Lussier SJ, Murrison LB, Numata M, O'Connor GT, Rivera-Spoljaric K, Phipatanakul W, Rothenberg ME, Seroogy CM, Zoratti EM, Castina S, Jackson DJ, Camargo CA, Johnson CC, Ethridge R, Ramratnam S, Stelzig L, Teach SJ, Togias AG, Fulkerson PC, Hartert TV, Seibold MA. The Common Cold Is Associated With Protection From SARS-CoV-2 Infections. J Infect Dis. 2025 Dec 20; 232(6):e920-e930.
-
Gartland M, Wang X, Liao Q, Li B, Du F, Krystal M, Tenorio AR, Pierce A, Castillo-Mancilla JR. Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study. HIV Med. 2026 Mar; 27(3):386-396.
-
Douglas OR, Low D, Maheria P, Thomas KK, Brown E, Hassan SA, Odhiambo F, Karauki E, Yongo N, Oyaro P, Abuogi LL, Patel RC. Associations between recent intimate partner violence and sustained viral suppression among pregnant and postpartum women living with HIV in western Kenya: A secondary analysis of a prospective cohort (Opt4Mamas). Int J Gynaecol Obstet. 2026 May; 173(2):963-973.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|